Actively Recruiting
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Led by Bristol-Myers Squibb · Updated on 2026-03-30
35
Participants Needed
4
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
CONDITIONS
Official Title
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
- Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
- Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
You will not qualify if you...
- Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason.
- Participants must not have any evidence of active Tuberculosis (TB).
- Other protocol-defined Inclusion/Exclusion criteria apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Local Institution - 0001
Farmington, Connecticut, United States, 06030
Withdrawn
2
New York University School Of Medicine
New York, New York, United States, 10155
Actively Recruiting
3
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
4
Local Institution - 0003
Jackson, Tennessee, United States, 38305
Withdrawn
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here